SG191054A1 - Novel pharmaceutical composition - Google Patents

Novel pharmaceutical composition Download PDF

Info

Publication number
SG191054A1
SG191054A1 SG2013044037A SG2013044037A SG191054A1 SG 191054 A1 SG191054 A1 SG 191054A1 SG 2013044037 A SG2013044037 A SG 2013044037A SG 2013044037 A SG2013044037 A SG 2013044037A SG 191054 A1 SG191054 A1 SG 191054A1
Authority
SG
Singapore
Prior art keywords
compound
suitably
tablets
drug
amount
Prior art date
Application number
SG2013044037A
Other languages
English (en)
Inventor
Douglas J Demarini
Ngocdiep T Le
Francisco Henriquez
Lihong Wang
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG191054(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of SG191054A1 publication Critical patent/SG191054A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG2013044037A 2010-12-20 2011-12-20 Novel pharmaceutical composition SG191054A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20
PCT/US2011/066021 WO2012088033A2 (en) 2010-12-20 2011-12-20 Novel pharmaceutical composition

Publications (1)

Publication Number Publication Date
SG191054A1 true SG191054A1 (en) 2013-08-30

Family

ID=46314827

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013044037A SG191054A1 (en) 2010-12-20 2011-12-20 Novel pharmaceutical composition

Country Status (38)

Country Link
US (5) US20130266649A1 (enExample)
EP (4) EP4159204B1 (enExample)
JP (2) JP6126014B2 (enExample)
KR (1) KR101911109B1 (enExample)
CN (1) CN103998041B (enExample)
AR (2) AR084102A1 (enExample)
AU (1) AU2011349422B2 (enExample)
BR (1) BR112013015602B1 (enExample)
CA (1) CA2822701C (enExample)
CL (1) CL2013001779A1 (enExample)
CR (1) CR20130352A (enExample)
CY (1) CY1123376T1 (enExample)
DK (3) DK4159204T3 (enExample)
DO (1) DOP2013000138A (enExample)
EA (1) EA025198B1 (enExample)
ES (3) ES2982775T3 (enExample)
FI (2) FI4159204T3 (enExample)
HR (3) HRP20240564T1 (enExample)
HU (3) HUE066526T2 (enExample)
IL (1) IL226855A (enExample)
JO (1) JO3594B1 (enExample)
LT (3) LT4159204T (enExample)
MA (1) MA34883B1 (enExample)
MX (1) MX2013007073A (enExample)
MY (1) MY170501A (enExample)
NZ (1) NZ612157A (enExample)
PE (1) PE20140040A1 (enExample)
PH (1) PH12013501209A1 (enExample)
PL (3) PL4159205T3 (enExample)
PT (3) PT4159205T (enExample)
RS (2) RS65496B1 (enExample)
SG (1) SG191054A1 (enExample)
SI (3) SI2654736T1 (enExample)
TW (1) TWI505828B (enExample)
UA (1) UA113158C2 (enExample)
UY (1) UY33818A (enExample)
WO (1) WO2012088033A2 (enExample)
ZA (1) ZA201304189B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
PT2884979T (pt) 2012-08-17 2019-09-04 Hoffmann La Roche Terapêuticas combinadas para o melanoma, compreendendo a administração de cobimetinib e vemurafinib
IN2015DN04094A (enExample) * 2012-11-30 2015-10-09 Glaxosmithkline Llc
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1(2H)-基苯基乙酰胺的衍生物及其应用
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) * 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
EP4613333A3 (en) 2016-08-10 2025-10-29 F. Hoffmann-La Roche AG Pharmaceutical compositions comprising akt protein kinase inhibitors
RU2627692C1 (ru) * 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
WO2018095403A1 (zh) 2016-11-25 2018-05-31 江苏恒瑞医药股份有限公司 一种吡啶酮类衍生物药物组合物及其制备方法
CN110494166B (zh) 2017-05-02 2022-11-08 诺华股份有限公司 组合疗法
KR102881316B1 (ko) 2019-05-13 2025-11-05 노파르티스 아게 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태
TW202116314A (zh) * 2019-07-11 2021-05-01 美商普雷西斯精密藥品公司 T型鈣離子通道調節劑之調配物及其使用方法
AU2020326612B2 (en) 2019-08-02 2025-10-23 Onehealthcompany, Inc. Treatment of canine cancers
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
EP4444299A1 (en) 2021-12-06 2024-10-16 My Personal Therapeutics Ltd A combination treatment for cancer
WO2024171019A1 (en) * 2023-02-13 2024-08-22 Alembic Pharmaceuticals Limited Pharmaceutical composition of trametinib and process of preparation thereof
WO2025132408A2 (en) 2023-12-21 2025-06-26 Synthon B.V. Solvates of trametinib

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
PL1761528T3 (pl) * 2004-06-11 2008-05-30 Japan Tobacco Inc Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
WO2009018238A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
US7955622B2 (en) * 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
CA2668724A1 (en) * 2006-11-09 2008-05-22 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) * 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
US8414918B2 (en) * 2007-09-25 2013-04-09 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8822482B2 (en) * 2008-07-08 2014-09-02 Beta Pharma, Inc. Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof
MX2012003546A (es) 2009-09-23 2012-09-07 Glaxosmithkline Llc Combinacion.
US20120283278A1 (en) 2009-09-23 2012-11-08 Melissa Dumble Combination
MX2012003779A (es) 2009-09-28 2012-06-01 Glaxosmithkline Llc Combinacion.
DK4159217T3 (da) 2009-10-16 2024-08-12 Novartis Ag Kombination, der omfatter en mek-hæmmer og en b-raf-hæmmer
AU2010322105B2 (en) 2009-11-17 2014-05-08 Novartis Ag Combination
EP2608790A4 (en) 2010-08-26 2014-04-02 Glaxosmithkline Llc PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit
CZ2015278A3 (cs) 2015-04-24 2016-11-02 Zentiva, K.S. Krystalické formy trametinibu

Also Published As

Publication number Publication date
HRP20240564T1 (hr) 2024-09-27
SI4159204T1 (sl) 2024-06-28
PT4159205T (pt) 2024-05-08
WO2012088033A3 (en) 2014-03-13
SI2654736T1 (sl) 2020-10-30
EA025198B1 (ru) 2016-11-30
RS65496B1 (sr) 2024-06-28
HUE066525T2 (hu) 2024-08-28
CL2013001779A1 (es) 2014-06-27
HRP20201409T1 (hr) 2020-11-27
HUE066526T2 (hu) 2024-08-28
JP6126014B2 (ja) 2017-05-10
JO3594B1 (ar) 2020-07-05
BR112013015602A2 (pt) 2017-02-21
PE20140040A1 (es) 2014-02-26
UY33818A (es) 2012-07-31
PL2654736T3 (pl) 2020-12-14
US20140037726A1 (en) 2014-02-06
PL4159205T3 (pl) 2024-06-24
DK4159204T3 (da) 2024-05-21
EP2654736B1 (en) 2020-07-01
ZA201304189B (en) 2014-02-26
CN103998041B (zh) 2016-08-17
US9155706B2 (en) 2015-10-13
US9399021B2 (en) 2016-07-26
US20120183613A1 (en) 2012-07-19
PH12013501209A1 (en) 2013-07-29
MX2013007073A (es) 2013-09-26
CR20130352A (es) 2013-12-18
PL4159204T3 (pl) 2024-07-01
EP4159204A1 (en) 2023-04-05
RS65497B1 (sr) 2024-06-28
FI4159204T3 (fi) 2024-04-22
DK4159205T3 (da) 2024-05-13
JP2014510704A (ja) 2014-05-01
EP2654736A4 (en) 2015-04-22
EP4159205B1 (en) 2024-02-14
CA2822701C (en) 2018-10-23
KR20130130028A (ko) 2013-11-29
LT4159205T (lt) 2024-05-10
US20130266649A1 (en) 2013-10-10
CA2822701A1 (en) 2012-06-28
LT4159204T (lt) 2024-05-10
ES2820536T3 (es) 2021-04-21
AR122185A2 (es) 2022-08-24
JP2017137299A (ja) 2017-08-10
DOP2013000138A (es) 2013-11-30
BR112013015602B1 (pt) 2022-03-03
TWI505828B (zh) 2015-11-01
PT4159204T (pt) 2024-05-07
TW201249441A (en) 2012-12-16
AR084102A1 (es) 2013-04-24
EP4159204B1 (en) 2024-02-14
NZ612157A (en) 2015-05-29
US8580304B2 (en) 2013-11-12
CY1123376T1 (el) 2021-12-31
US9271941B2 (en) 2016-03-01
EA201390913A1 (ru) 2014-04-30
US20140099365A1 (en) 2014-04-10
EP2654736A2 (en) 2013-10-30
CN103998041A (zh) 2014-08-20
HRP20240563T1 (hr) 2024-08-16
AU2011349422B2 (en) 2015-12-10
EP4159205A1 (en) 2023-04-05
EP3808343A1 (en) 2021-04-21
UA113158C2 (xx) 2016-12-26
ES2982775T3 (es) 2024-10-17
WO2012088033A2 (en) 2012-06-28
DK2654736T3 (da) 2020-09-14
US20140154316A1 (en) 2014-06-05
LT2654736T (lt) 2020-09-25
MA34883B1 (fr) 2014-02-01
KR101911109B1 (ko) 2018-10-23
FI4159205T3 (fi) 2024-04-23
IL226855A (en) 2017-04-30
SI4159205T1 (sl) 2024-06-28
PT2654736T (pt) 2020-09-24
AU2011349422A1 (en) 2013-05-02
MY170501A (en) 2019-08-08
HUE050788T2 (hu) 2021-01-28
ES2985024T3 (es) 2024-11-04

Similar Documents

Publication Publication Date Title
AU2011349422B2 (en) Novel pharmaceutical composition
AU2013352369B2 (en) Novel pharmaceutical composition
AU2018297656A1 (en) Novel pharmaceutical composition
HK40086699B (en) Novel pharmaceutical composition
HK40086699A (en) Novel pharmaceutical composition
HK40086707A (en) Novel pharmaceutical composition
HK40086707B (en) Novel pharmaceutical composition
HK40043030A (en) Novel pharmaceutical composition